Partnership celebrates the Blue Jackets’ 25th season and their longstanding commitment to literacy, education, and community ...
Phyrago is a novel formulation of Sprycel ® (dasatinib) designed to enable concomitant use with proton pump inhibitors (PPIs) and H 2 receptor antagonists (H 2 RAs). 1 Clinical data showed no ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...
Chronic myeloid leukemia (CML) is a type of cancer that affects blood-forming tissues. With appropriate treatment, it is possible for people with CML to experience remission. In the 1970s, the 5-year ...
Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...
6d
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...
The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...
A Charlotte-based library services company will close its doors next year. Baker & Taylor will shutter its headquarters off ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback